S&P 500

5.631,22

0,28%

Aumente o nível de sua negociação com nossas ferramentas poderosas e insights em tempo real, tudo em um só lugar.

Cadastre-se

Início
Investir
Ações
EUA
NASDAQ
Allos Therapeutics, Inc. (MM) (ALTH)
Allos Therapeutics, Inc. (MM) (ALTH) Notícias

ALTH

Allos Therapeutics, Inc. (MM) (ALTH)

Allos Therapeutics, Inc. (MM)

De:

Notícias regulamentadas

Procure um Texto:

Ordenação:

Notícias não regulamentadas

Apresentando as notícias mais relevantes sobre:NASDAQ:ALTH

<< Anterior 2 3 4 5 6 7 8 9 10 11 12 13 14 Próxima >>

Data	Hora	Fonte	Título	Código	Companhia
05/06/2006	10:00	PR Newswire (US)	Allos Therapeutics' EFAPROXYN(TM) Found to Reduce Tumor Hypoxia and HIF-1-alpha Expression in Human Breast Cancer Xenografts	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
25/05/2006	17:33	PR Newswire (US)	Allos Therapeutics Reports Restricted Stock Grant Under Nasdaq Marketplace Rule 4350	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/05/2006	09:00	PR Newswire (US)	Allos Therapeutics Reports First Quarter 2006 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
04/04/2006	09:00	PR Newswire (US)	Interim Analysis Supports Continuation of Allos Therapeutics' Pivotal Phase 3 Trial	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
10/03/2006	10:00	PR Newswire (US)	Allos Therapeutics Appoints Paul L. Berns as President and CEO	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
06/03/2006	10:00	PR Newswire (US)	Allos Therapeutics Reports 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
01/03/2006	10:00	PR Newswire (US)	Allos Therapeutics to Present at the 2006 Cowen Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
14/02/2006	11:00	PR Newswire (US)	Scheduled Combination of Allos Therapeutics' Pralatrexate Plus Gemcitabine Proves Superior to Methotrexate Plus Cytarabine in Mo	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
01/02/2006	11:00	PR Newswire (US)	Allos Therapeutics to Present at the 2006 BIO CEO & Investor Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/01/2006	22:22	PR Newswire (US)	Allos Therapeutics Announces CEO Succession Plans	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
03/01/2006	11:00	PR Newswire (US)	Results Published in Journal of Clinical Oncology Affirm Survival Benefit of EFAPROXYN(TM) in Patients with Brain Metastases Ori	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/12/2005	11:02	PR Newswire (US)	Retrospective Analysis Finds EFAPROXYN(TM) Extends Survival With Quality of Life in Patients With Brain Metastases Originating F	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
12/12/2005	11:00	PR Newswire (US)	PDX Shows Promising Activity in Patients With Resistant T-Cell Lymphomas	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/11/2005	11:02	PR Newswire (US)	Allos Therapeutics Appoints Timothy P. Lynch to Board of Directors	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
17/11/2005	11:01	PR Newswire (US)	Interim Phase 1 Data on RH1 Presented at AACR-NCI-EORTC Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/11/2005	11:00	PR Newswire (US)	Data From Phase 1 Clinical Trial of PDX (Pralatrexate) to be Presented at American Society of Hematology Annual Meeting	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
09/11/2005	11:02	PR Newswire (US)	Allos Therapeutics Reports Third Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
08/11/2005	11:02	PR Newswire (US)	Data on EFAPROXYN(TM) and RH1 to be Presented at Upcoming Scientific Conferences	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
21/10/2005	14:02	PR Newswire (US)	Allos Therapeutics Announces Dismissal of Securities Class Action Lawsuit	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
13/10/2005	10:01	PR Newswire (US)	Allos Therapeutics to Present at the 2005 BIO Investor Forum	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/10/2005	19:06	PR Newswire (US)	Allos Therapeutics Announces Withdrawal of European Marketing Authorization Application for REVAPROXYN(TM)	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
22/09/2005	10:00	PR Newswire (US)	Allos Therapeutics to Present at the UBS Global Life Sciences Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
07/09/2005	10:02	PR Newswire (US)	Allos Therapeutics to Present at the Bear Stearns Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
01/09/2005	10:00	PR Newswire (US)	Results Published in Journal of Clinical Oncology Demonstrate Survival Benefit of EFAPROXYN(TM) in Treating NSCLC Patients Recei	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
08/08/2005	10:01	PR Newswire (US)	Allos Therapeutics Reports Second Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
16/06/2005	16:28	PR Newswire (US)	Allos Therapeutics and Hovione Enter Into Manufacturing Agreement for EFAPROXYN(TM) Bulk Drug Substance	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/05/2005	19:46	PR Newswire (US)	Allos Therapeutics Announces Stockholder Approval of Share Exchange	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
19/05/2005	10:00	PR Newswire (US)	Allos Therapeutics to Present at the Needham & Company Biotechnology Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
05/05/2005	10:01	PR Newswire (US)	Allos Therapeutics Reports First Quarter 2005 Financial Results	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)
11/03/2005	08:00	PR Newswire (US)	Allos Therapeutics to Present at SG Cowen's Healthcare Conference	NASDAQ:ALTH	Allos Therapeutics, Inc. (MM)